Jacob Vincent Micallef - Apr 7, 2022 Form 4 Insider Report for VOLITIONRX LTD (VNRX)

Role
Chief Scientific Officer
Signature
/s/ Jacob Vincent Micallef
Stock symbol
VNRX
Transactions as of
Apr 7, 2022
Transactions value $
$0
Form type
4
Date filed
4/8/2022, 04:04 PM
Previous filing
Nov 5, 2021
Next filing
Jun 24, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VNRX Common Stock Award $0 +8.44K +8.37% $0.00 109K Apr 7, 2022 Direct F1
holding VNRX Common Stock 22K Apr 7, 2022 By Spouse
holding VNRX Common Stock 38.1K Apr 7, 2022 By Borlaug Limited F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VNRX Stock Option (Right to Buy) Award $0 +15.6K $0.00 15.6K Apr 7, 2022 Common Stock 15.6K $3.40 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On August 3, 2021, the reporting person was awarded 24,125 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 8,443 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two installments of 4,221 units and 4,222 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.
F2 The shares of common stock are held directly by Borlaug Limited. Dr. Micallef is a controlling director of Borlaug Limited and has voting and dispositive control over the shares of common stock held by Borlaug Limited.
F3 On August 3, 2021, the reporting person was granted an option to purchase 44,457 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 15,559 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 7,779 shares and 7,780 shares on each of August 3, 2022 and August 3, 2023, respectively.